No Data
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability
Citius Oncology Analyst Ratings
Express News | Citius Oncology Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $3
US Manufacturing Index Rises To 43, Highest Since 2020
Citius Pharmaceuticals Reports Positive Early Stage Results of Cancer Combo Treatment
Express News | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients With Recurrent Solid Tumors
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
, I'll continue with the operation